A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer.

Trial Profile

A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs IMM 101 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms IMAGE 1
  • Sponsors Immodulon Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Sep 2016 Results published in the British Journal of Cancer
    • 06 May 2016 End date in EudraCT is closer to planned end date in NCT, I have completed the trial as NCT is not updated from long back.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top